Onco Actu du 12 mai 2020

	1.1 BIOLOGIE - GÉNOME
Genetic Ancestry Linked to Differences in Molecular Features of Cancers [Genome Web] Using data from The Cancer Genome Atlas, researchers from the Broad Institute and elsewhere examined ancestry-mediated effects on normal and tumor tissue. As they reported in Cancer Cell on Monday, the scientists found tissue-specific differences associated with ancestry, some of which are related to cancer, such as increased FBXW7 mutations in patients of African ancestry, and decreased immune activity in bladder cancer among patients of East Asian ancestry.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows [NCI] Conducted in Australia, the trial included men diagnosed with localized prostate cancer that was thought to be at high risk of spreading beyond the prostate.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Advanced, Fatal Breast Cancers Reduced Through Mammography Screening [AJMC] The Swedish Cancer Registry provided the study team with patient data on breast cancer diagnoses, and The Swedish Cause of Death Register of the Swedish National Board of Health and Welfare supplied the causes and dates of death for the 549,091 patients followed for the study, or almost 30% of the population eligible for screening.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
HKBU-led research team develops novel anti-viral targeted drug for nasopharyngeal cancer treatment [Hong Kong Baptist University] Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency. These research results were published in the international journal Proceedings of the National Academy of Sciences.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Bluebird nabs $200M in early payout from retooled Bristol Myers BCMA deal [Fierce Biotech] The cash will help bluebird build its lentiviral vector manufacturing site in North Carolina “to support the U.S. commercial market for ide-cel and for bluebird bio’s pipeline,” while BMS will pick up vector manufacturing outside the U.S.
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement [bluebird bio] Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Cancer-eating immune cells kitted out with CARs [Nature Biotechnology] By the end of the year, Carisma aims to launch first-in-human trials with an autologous CAR-macrophage therapy directed against tumors expressing human epidermal growth factor receptor 2 (HER2).
	5.12.6 IMMUNOTHÉRAPIES - AMM
EMA Does Not Recommend Extending the Use of Pembrolizumab [ESMO] Application concerned first-line treatment in patients with NSCLC and PD-L1 scores between 1 and 49%.
	5.2 PHARMA
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval [EndPoints] Next up on the docket for AstraZeneca and Merck’s Lynparza is an approval for a subset of patients with metastatic castration-resistant prostate cancer, after the companies reported a statistically significant improvement in overall survival.
	5.2.6 PHARMA - BIOTECH
Immunomedics raises $459M as Trodelvy breast cancer launch kicks off amid COVID-19 [Fierce Pharma] Launching a drug amid the pandemic is no cakewalk, but Immunomedics decided to do it anyway with first-in-class Trodelvy in triple-negative breast cancer—and it's drummed up some extra money to help.
	5.4 TRAITEMENTS - ECONOMIE
NICE backs Roche's Kadcyla for HER2-positive early breast cancer [Pharma Times] Kadcyla costs on average £51,000 per patient for a course of treatment at its full list price, but Roche has agreed a confidential commercial arrangement so that it's available to the NHS with a discount.
	5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
Bristol Myers Squibb Research at ASCO Demonstrates Diverse Approaches in Treating Cancer to Improve Outcomes for Patients [BMS] Overall survival results from CheckMate–9LA and CheckMate-227 (three-year follow-up) in first-line lung cancer.
	6.1 OBSERVATION
Antihistamines may help patients with malignant melanoma [Lund University] In the study, the researchers examined the use of six antihistamines in patients diagnosed with malignant melanoma; desloratadine, cetirizine, loratadine, clemastine, ebastine and fexofenadine.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Lower Antibodies Rate in Cancer Patients After Symptomatic COVID-19 Than In Healthcare Workers [ESMO] Results from an analysis involving both cancer patients and healthcare workers at Centre Léon Bérard in Lyon, France, showed that patients with cancer had a significantly lower detection rate of SARS-COV2 antibodies 15 days or later after COVID-19 symptoms and RT-PCR-positive test than healthcare workers.
Decline in cancer diagnoses due to corona crisis of international interest [University of Twente] A quarter fewer cases of cancer have been diagnosed for several weeks, as found by the Netherlands Cancer Registry based on initial diagnoses in the PALGA pathology database.